| Autor: |
Cockey SG; University of South Florida Health Morsani College of Medicine, Tampa, FL, USA., Zhang H; Department of Pathology, Division of Hematopathology, Moffitt Cancer Center, Tampa, FL, USA., Hussaini M; Department of Pathology, Division of Hematopathology, Moffitt Cancer Center, Tampa, FL, USA., Zhang L; Department of Pathology, Division of Hematopathology, Moffitt Cancer Center, Tampa, FL, USA., Moscinski L; Department of Pathology, Division of Hematopathology, Moffitt Cancer Center, Tampa, FL, USA., Yang E; Department of Hematology and Oncology, Berkey Preparatory School of Tampa, Tampa, FL, USA., Li J; Department of Pathology, Division of Hematopathology, Moffitt Cancer Center, Tampa, FL, USA., Wang L; Department of Hematology and Oncology, Guthrie Clinic Cancer Center, Guthrie Robert Packer Hospital, Sayre, PA, USA., Song J; Department of Pathology, Division of Hematopathology, Moffitt Cancer Center, Tampa, FL, USA. |
| Abstrakt: |
The mutations in SRSF2 and TET2 genes are frequently present in various myeloid neoplasms. The potential impact of SRSF2 / TET2 co-mutations on patient survival is incompletely understood. We identified 412 patients with SRSF2 / TET2 co-mutations from our NextGen sequencing database of around 8000 patients and reported likely the largest cohort study. Our study demonstrated the presence of these co-mutations in a spectrum of myeloid neoplasms, which show different genetic and molecular characteristics. Most of the patients with these co-mutations had normal karyotype. Interestingly, our study provided insights into the prevalence of additional mutations such as ASXL1 , RUNX1 , and KRAS with this co-mutation and their potential impact on patients' prognosis. We found that ASXL1 , RUNX1 , and KRAS can negatively impact these patients' survival with different impacts in different morphological diagnosis categories, suggesting a complex interaction between these genes. This study underscores the need for personalized approaches in the treatment of myeloid neoplasms. |
